National Comprehensive Cancer Network



About NCCN

Ovarian Cancer Panel - Disclosures as of 7/13/2012

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Ronald D. Alvarez, MD

Morphotek Inc.;
Pfizer Inc.

Genentech, Inc.;
Astellas

None

None

7/13/2012

Deborah K. Armstrong, MD

Genentech, Inc.;
MedImmune Inc.;
Morphotek Inc.;
Astellas

Genentech, Inc.;
Morphotek Inc.

None

None

6/28/2012

Robert Burger, MD, FACOG, FACS

Genentech, Inc.

Champions Biotech;
Clovis Oncology;
Endocyte;
Nektar;
sanofi-aventis U.S.

None

GlaxoSmithKline

3/22/2013

Lee-may Chen, MD

None

None

None

None

4/11/2013

Larry Copeland, MD

None

Boehringer Ingelheim GmbH;
Eisai Inc.;
Genentech, Inc.

None

None

3/9/2013

Marta Ann Crispens, MD

Morphotek Inc.;
Spirogen

None

None

None

5/5/2011

Mary Dwyer, MS

None

None

None

None

3/26/2013

Lauren Gallagher, RPh, PhD

None

None

None

None

6/5/2012

David M. Gershenson, MD

AstraZeneca Pharmaceuticals LP;
Genentech, Inc.;
National Cancer Institute

None

Johnson & Johnson;
Elsevier;
Informa;
Up to Date;
Pfizer Inc.

National Cancer Institute

8/22/2012

Heidi J. Gray, MD

Abbott Laboratories;
Prima Biomed

Prima Biomed

None

None

4/24/2013

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

10/23/2012

Ardeshir Hakam, MD

None

None

None

None

3/7/2013

Laura J. Havrilesky, MD

BD TriPath Oncology

BD-TriPath Oncology

None

None

4/3/2012

Miranda Hughes, PhD

None

None

None

None

4/10/2013

Carolyn Johnston, MD

None

None

None

american cancer society-great lakes division;
michigan cancer consortium

8/19/2012

Shashikant Lele, MD

None

None

None

None

4/24/2013

Lainie Martin, MD

None

None

None

None

4/26/2013

Ursula A. Matulonis, MD

AstraZeneca Pharmaceuticals LP;
Bristol-Myers Squibb Company;
Eli Lilly and Company;
Genentech, Inc.;
Merck & Co., Inc.

Clovis;
Pathway Therapeutics

None

None

7/3/2012

Joan S. McClure, MS

None

None

None

None

7/23/2012

Robert J. Morgan, MD, FACP

NIH-CTEP

None

None

None

3/12/2013

David M. O'Malley, MD

Genentech, Inc.

Genentech, Inc.;
Johnson & Johnson

None

None

3/20/2013

Richard T. Penson, MD, MRCP

Amgen Inc.;
AstraZeneca Pharmaceuticals LP;
Eisai Inc.;
Eli Lilly and Company;
Genentech, Inc.;
ImClone Systems Incorporated;
Endocyte Inc.

AstraZeneca Pharmaceuticals LP;
Genentech, Inc.;
Biomarin Pharmaceuticals, Inc.;
Clovis Oncology;
Lifecore Biomedical

None

None

3/7/2013

Matthew A. Powell, MD

Bristol-Myers Squibb Company;
Eisai Inc.

Merck & Co., Inc.

None

None

4/10/2013

Steven W. Remmenga, MD

None

None

None

None

5/6/2013

Paul Sabbatini, MD

Prim Biomed

None

None

None

8/16/2012

Joseph T. Santoso, MD

None

Jannsen Pharmaceutica Products, LP;
lab cor;
vermillion

None

None

10/11/2012

Julian C. Schink, MD

None

Genentech, Inc.

None

None

3/8/2013

Nelson Teng, MD, PhD

GOG

None

None

None

3/5/2013

Theresa L. Werner, MD

None

None

None

None

4/10/2013

 

About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved